XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q1)Nov 30, 2024 | (FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (Q3)May 31, 2024 | (Q2)Feb 29, 2024 | (Q1)Nov 30, 2023 | (FY)Aug 31, 2023 | (Q4)Aug 31, 2023 | (Q3)May 31, 2023 | (Q2)Feb 28, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 464.51%13.57M | -58.88%2.4M | ||||||||
Net income from continuing operations | ---- | -165.47%-110.89M | ---- | ---- | ---- | ---- | 52.09%-41.77M | ---- | ---- | ---- |
Operating gains losses | ---- | 134.39%474.13K | ---- | ---- | ---- | ---- | 74.40%-1.38M | ---- | ---- | ---- |
Depreciation and amortization | ---- | -25.26%6.77M | ---- | ---- | ---- | ---- | -36.93%9.06M | ---- | ---- | ---- |
Deferred tax | ---- | -95.07%576.13K | ---- | ---- | ---- | ---- | 380.90%11.67M | ---- | ---- | ---- |
Other non cash items | ---- | 44.60%13.04M | ---- | ---- | ---- | ---- | -46.20%9.02M | ---- | ---- | ---- |
Change In working capital | ---- | 6.43%-9.21M | ---- | ---- | ---- | ---- | -329.72%-9.84M | ---- | ---- | ---- |
-Change in receivables | ---- | -1,895.51%-6.6M | ---- | ---- | ---- | ---- | 113.66%367.81K | ---- | ---- | ---- |
-Change in inventory | ---- | -25.32%111.12K | ---- | ---- | ---- | ---- | 69.11%148.81K | ---- | ---- | ---- |
-Change in payables and accrued expense | ---- | 658.23%10.33M | ---- | ---- | ---- | ---- | -107.53%-1.85M | ---- | ---- | ---- |
-Change in other current liabilities | ---- | -2.33%-11.33M | ---- | ---- | ---- | ---- | 28.79%-11.07M | ---- | ---- | ---- |
-Change in other working capital | ---- | -166.62%-1.71M | ---- | ---- | ---- | ---- | 219.91%2.57M | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -143.10%-5.66M | 464.51%13.57M | 1,585.22%11.1M | 1,240.93%10.64M | -191.62%-5.48M | 25.27%-2.33M | -58.88%2.4M | -95.12%658.59K | -102.45%-932.87K | --5.99M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -84.03%-10.52M | 94.49%-5.72M | ||||||||
Net PPE purchase and sale | ---- | 193.06%5.32M | ---- | ---- | ---- | ---- | 46.80%-5.72M | ---- | ---- | ---- |
Net business purchase and sale | ---- | -633,316.60%-13M | ---- | ---- | ---- | ---- | ---2.05K | ---- | ---- | ---- |
Net investment purchase and sale | ---- | ---2.85M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 281.22%3.56M | -84.03%-10.52M | -602.99%-13.84M | 149.60%1.18M | 219.51%4.03M | -203.00%-1.97M | 94.49%-5.72M | -105.05%-1.97M | 3.02%-2.39M | ---3.37M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 71.56%-9.18M | -356.80%-32.27M | ||||||||
Net issuance payments of debt | ---- | --0 | ---- | ---- | ---- | ---- | 90.77%-18.57M | ---- | ---- | ---- |
Net common stock issuance | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Net other financing activities | ---- | 33.03%-9.18M | ---- | ---- | ---- | ---- | -106.37%-13.7M | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -2,015.24%-4.44M | 71.56%-9.18M | 100.65%141.93K | -68.01%-7.89M | 76.79%-1.21M | 66.28%-210K | -356.80%-32.27M | 81.43%-21.98M | 91.74%-4.69M | ---5.22M |
Net cash flow | ||||||||||
Beginning cash position | -11.95%54.33M | -34.25%60.9M | -31.79%59.41M | -41.68%54.94M | -43.88%57.24M | -38.40%61.7M | -50.67%92.63M | -46.50%87.1M | -46.82%94.22M | --101.99M |
Current changes in cash | -45.62%-6.56M | 82.78%-6.13M | 88.83%-2.6M | 149.17%3.94M | -2.07%-2.66M | -146.13%-4.5M | 58.28%-35.58M | 64.61%-23.29M | 62.21%-8.02M | ---2.61M |
Effect of exchange rate changes | -141.95%-263K | -111.17%-469.51K | -127.98%-679.29K | -41.49%524.16K | 93.36%-44.78K | -59.92%627K | 10.02%4.2M | 75.99%2.43M | -86.92%895.88K | ---674.3K |
End cash Position | -17.84%47.51M | -11.35%54.31M | -11.35%54.31M | -31.79%59.41M | -44.76%54.53M | -42.12%57.82M | -42.38%61.25M | -42.38%61.25M | -46.50%87.1M | --98.71M |
Free cash flow | -143.10%-5.66M | 240.89%8.69M | 178.57%6.22M | 1,240.93%10.64M | -191.62%-5.48M | 25.27%-2.33M | -17.18%-6.17M | -429.87%-7.91M | -102.45%-932.87K | --5.99M |
Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |